Effects of SGLT-2 inhibitors and GLP-1 receptor agonists on liver function in patients with non-alcoholic fatty liver disease and type 2 diabetes - Scorecard - MDSpire

Effects of SGLT-2 inhibitors and GLP-1 receptor agonists on liver function in patients with non-alcoholic fatty liver disease and type 2 diabetes

  • By

  • Wancheng Guo

  • Wenhe Li

  • Xianlin Li

  • Wen Shi

  • Yan Yan

  • Ting Yan

  • Jie Zhou

  • Yujie Huang

  • June 3, 2026

  • 0 min

Share

Clinical Scorecard: Impact of SGLT-2 Inhibitors versus GLP-1 Receptor Agonists on Hepatic Function in Individuals with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

At a Glance

CategoryDetail
Condition
Key MechanismsRevise to specify the direct hepatoprotective effects of SGLT2 inhibitors and clarify the indirect effects of GLP-1 receptor agonists.
Target Population
Care Setting

Key Highlights

  • weight_change

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • S
      • p
      • e
      • c
      • i
      • f
      • y
      • t
      • h
      • e
      • r
      • e
      • c
      • o
      • m
      • m
      • e
      • n
      • d
      • e
      • d
      • f
      • r
      • e
      • q
      • u
      • e
      • n
      • c
      • y
      • o
      • f
      • l
      • i
      • v
      • e
      • r
      • e
      • n
      • z
      • y
      • m
      • e
      • m
      • o
      • n
      • i
      • t
      • o
      • r
      • i
      • n
      • g
      • d
      • u
      • r
      • i
      • n
      • g
      • t
      • r
      • e
      • a
      • t
      • m
      • e
      • n
      • t
      • .

      Risks

        Patient & Prescribing Data

        Adults aged ≥20 years with NAFLD and Type 2 Diabetes.

        SGLT2 inhibitors may provide direct hepatoprotective benefits compared to GLP-1 receptor agonists.

        Clinical Best Practices

        • additions

        Related Resources & Content

        Original Source(s)

        Effects of SGLT-2 inhibitors and GLP-1 receptor agonists on liver function in patients with non-alcoholic fatty liver disease and type 2 diabetes

        • by Wancheng Guo, Wenhe Li, Xianlin Li, Wen Shi, Yan Yan, Ting Yan, Jie Zhou, Yujie Huang

        • June 3, 2026

        Related Content

        East is East

        Is ophthalmology in the East really that much different to the West?

        Effect of Ethnicity on the Relationship Between Telomere Length and Metabolic Markers in Kuwait

        California considers seal of approval for foods that are not ultra-processed